Prospective, open-label, single arm pilot study evaluating the effect on virological response of the switch from tacrolimus to cyclosporin associated with a peginterferon alfa-2a / ribavirin bitherapy, in non-responder or with recurrent VHC+ disease liver transplanted patients.

Trial Profile

Prospective, open-label, single arm pilot study evaluating the effect on virological response of the switch from tacrolimus to cyclosporin associated with a peginterferon alfa-2a / ribavirin bitherapy, in non-responder or with recurrent VHC+ disease liver transplanted patients.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Liver transplant rejection
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Mar 2012 Actual patient number is 11 according to ClinicalTrials.gov.
    • 01 Mar 2012 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 01 Mar 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top